



Press Release

Thursday, April 22, 2010

Strides Arcolab Limited,
Strides House,
Bannerghatta Road,
Bangalore – 560076, India

BSE: 532531
NSE: STAR

Strides today announced Q1'10 financials Delivers strong growth and Performance is in line with guidance

Financial Highlights

(Source Q1-10 consolidated unaudited results)

Revenues at Rs.382 Crores (Rs.292 Crores in Q1 '09)	Up 31%
EBIDTA at Rs.86 Crores (Rs.50 Crores in Q1 '09)	Up 73%
Improved EBITDA Margin from 17% to 23%	Up 35%
PBT at Rs.50 Crores (Rs.11 Crores in Q1 '09)	Up 357%
PAT after Minority at Rs.40 Crores (Rs.11 Crores in Q1'09)	Up 279%
EPS (Not annualized) at Rs.9.43 (Rs.2.40 in Q1'09)	Up 293%


- ✓ Consolidated Revenues include R&D and Licensing Income of Rs.83 Crores
- ✓ Standalone Revenues at Rs.133 Crores , up by 19% and PAT at Rs 10 Crores, up by 100+ %
- ✓ Redeemed FCCB's of USD 34 Million (Redemption Value - USD 46.5Mn), due on April 19, 2010

Strategic Highlights

- ✓ Collaboration with Pfizer on Specialty Sterile Injectables for US Market
- ✓ Acquired Steriles Penems & Penicillin facility at Campos in Brazil
- ✓ Secured 100% ownership in Onco Therapies Ltd, India and Onco Laboratories Ltd, Cyprus
- ✓ Expression of interest to acquire Minority Shares in Ascent Pharmahealth, Australia

Regulatory Approvals

- ✓ Received 6 ANDA approvals from USFDA, YTD 2010. Total approvals at 38, **23 in Specialties**
- ✓ 4 ANDA filings with USFDA, YTD 2010. Total filings at 129, **97 in Specialties**
- ✓ 91 pending approvals with USFDA



Commenting on the performance, Mr. Arun Kumar, Group CEO said “I am pleased with the continued scale-up in growth momentum driven by both Specialty and Pharma Businesses backed by Strong licensing Income during the quarter, which is also the first quarter post reorganization”.

Business-Wise Performance

Rs. Crores

Business	Revenues				EBITDA			
	Q1'2010	%	Q1'2009	Growth %	Q1'2010	%	Q1'2009	Growth %
Specialties	123	32%	96	27%	43	50%	21	101%
Pharma	259	68%	196	32%	43	50%	29	52%
Reported Financials	382	100%	292	31%	86	100%	50	73%

Regulatory Status

Particulars	Business	Dec 2009	YTD 2010	Total – Till date
Filings	Pharma	32	0	32
	Specialties	93	4	97
	Total	125	4	129
Approvals	Pharma	14	1	15
	Specialties	17	6	23
	Total	31	7	38
Pending Approvals				91





Strides Arcolab Limited: Leadership through Partnering

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 14 manufacturing facilities across 6 countries and has a marketing presence in more than 60 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore. Additional information is available at the company's website at www.stridesarco.com.

For further information, please contact:

<u>Strides</u>	<u>PR Consultancy</u>
Mr. T.S. Rangan, Group CFO +91 80 66580115	Mahesh Nair, Corporate Voice/Weber Shandwick +91 9880376648 maheshn@corvoshandwick.co.in
Mr. Kannan. N (Investors) +91 80 66580751	Kasturi Wasmatkar +91 9916728393 kasturi@corvoshandwick.co.in
Melissa Arulappan (Media) +91 98450 22389	

